

OCT. 6. 2004, 4:08PM AVENTIS US PAT DEPT  
TO:US USPTO GENERAL

RECEIVED  
CENTRAL FAX CENTER

NO. 8376 P. 1

OCT 06 2004


PTO/BB/21 (09-04)


Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/674,480
	Filing Date	September 30, 2003
	First Named Inventor	KLEIN et al.
	Art Unit	1825
	Examiner Name	C. Chang
	Attorney Docket Number	USA2797 US CNT
Total Number of Pages in This Submission	22	

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Updated - Application Data Sheet
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.63	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	AVENTIS PHARMACEUTICALS INC.		
Signature			
Printed name	Joseph D. Rossi		
Date	October 06, 2004	Reg. No.	47,038

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Paul Irvine	Date	October 06, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OCT. 6. 2004, 4:09PM

AVENTIS US PAT DEPT

RECEIVED  
CENTRAL FAX CENTER

NO. 8376 P. 3

OCT 06 2004

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**In re Application of  
**KLEIN, et al.**


Examiner: C. Chang

Art Unit: 1625

Application No.: 10/674,480

Filed: September 30, 2003

Title: **PIPERIDIDINYL AND N-  
AMIDINOPIPERIDINYL  
DERIVATIVES**

TELEFAX CERTIFICATE	
i hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on	
Date of Deposit	October 6, 2004
Printed Name of Person Signing Certificate	Paul Irvine
Signature	

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Transmitted herewith is an amendment in the above-identified application.

☐ No additional fee is required.

The fee has been calculated as shown below.

(1)	(2) CLAIMS REMAINING AFTER AMENDMENT*	(3)	(4) HIGHEST NUMBER PREVIOUSLY PAID FOR** ***	(5) PRESENT EXTRA	(6) RATE	(7) ADDITIONAL FEE
TOTAL CLAIMS	35	MINUS	33	2	18.00	36.00
INDEPENDENT CLAIMS	2	MINUS	3	0	86.00	0
MULTI-DEPENDENT CLAIMS(S), Per Application (290.00)						
TOTAL AMENDMENT FEE FOR THIS AMENDMENT						36.00


\* If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.

\*\* If the "Highest Number Previously Paid For" in Total Claims is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid For" in (Independent Claims) is less than 3, write "3" in this space.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 which may be required by this paper or credit any overpayment to Account No. 18-1982. Two duplicate copies of this paper are enclosed.

Respectfully submitted,

  
Joseph D. Rossi, Registration No. 47,038  
Attorney for ApplicantAventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-3410  
Telefax (908) 231-2626  
Aventis Docket No. USA2797 US CNT

OCT. .6. 2004 4:10PM

AVENTIS US PAT DEPT

NO. 8376 P. 7

USA2797 US CNT

**RECEIVED**  
**CENTRAL FAX CENTER**

OCT 0 6 2004

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**KLEIN, et al.**

Examiner: C. Chang

Art Unit: 1625

Application No.: 10/674,480

Filed: September 30, 2003

Title: **PIPERIDIDINYL AND N-  
AMIDINOPIPERIDINYL  
DERIVATIVES**

**TELEFAX CERTIFICATE**  
I hereby certify that this correspondence is being  
transmitted via facsimile to the Commissioner for  
Patents, Alexandria, VA 22313, on

**October 6, 2004**

Date of Transmission

Signature

**Preliminary Amendment Pursuant to 37 C.F.R. § 1.115 and**  
**Response to the Restriction Requirement**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

This paper is in response to the Office Action dated June 9, 2004 ("the Office Action"), in which a restriction requirement was issued in connection with the above-identified patent application. This paper is also a Preliminary Amendment pursuant to 37 C.F.R. § 115 in connection with the above-identified patent application. Filed concurrently herewith is a Petition for Extension of Time pursuant to 37 C.F.R. § 1.136(a) for three (3) months.

Applicants respectfully request the application be amended, without prejudice, prior to examination as follows: